395099-05-5

Basic information

• Product Name: 5-AMINO-3-PHENYL-1H-INDAZOLE
• Synonyms: 5-AMINO-3-PHENYL-1H-INDAZOLE;1H-Indazol-5-aMine, 3-phenyl-
• CAS NO: 395099-05-5
• Molecular Formula: C₁₃H₁₁N₃
• Molecular Weight: 209.25
• Mol File: 395099-05-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-AMINO-3-PHENYL-1H-INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-AMINO-3-PHENYL-1H-INDAZOLE(395099-05-5)
• EPA Substance Registry System: 5-AMINO-3-PHENYL-1H-INDAZOLE(395099-05-5)

Safety Data

• Hazardous Substances Data: 395099-05-5(Hazardous Substances Data)

Usage

General Description

5-AMINO-3-PHENYL-1H-INDAZOLE is an organic compound consisting of a phenyl ring and an indazole ring with an amino group attached to the third carbon atom of the indazole ring. It is a heterocyclic compound with potential pharmacological activities, and it is commonly used as a building block in the synthesis of various pharmaceuticals and organic compounds. The compound has been studied for its potential anti-cancer, anti-inflammatory, and anti-diabetic properties, and its structure gives it potential as a drug candidate for various therapeutic uses. Additionally, its unique chemical structure and reactivity make it a valuable tool for medicinal chemistry and drug development.

Upstream product

• 293758-67-5 5-nitro-3-phenyl-1H-indazole 
• 183110-88-5 2-bromo-5-nitro-benzophenone 
• 7440-05-3 palladium 
• 478837-59-1 3-bromo-1H-indazol-5-amine 
• 98-80-6 phenylboronic acid 
• 5401-94-5 5-nitroindazole 
• 67400-25-3 3-bromo-5-nitro-1H-indazole 

Downstream Products

• 13097-01-3 3-phenyl-1H-indazole 
• 1348469-62-4 N-[4-(3-phenyl-1H-indazol-5-ylsulfamoyl)phenyl]acetamide 
• 1347324-34-8 3-nitro-N-(3-phenyl-1H-indazol-5-yl)benzenesulfonamide 
• 599183-11-6 2-methylsulfonyl-N-(3-phenyl-1H-indazol-5-yl)benzenesulfonamide 

Relevant articles and documents

INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS

The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.

FUSED TETRAZOLES AS LRRK2 INHIBITORS

The present invention is directed to fused tetrazoles of formula (IA) which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.

Efficient synthesis of 3-aryl-1H-indazol-5-amine by Pd-catalyzed Suzuki-Miyaura cross-coupling reaction under microwave-assisted conditions

Various 3-aryl-1H-indazol-5-amine derivatives were synthesized by Pd-catalyzed Suzuki-Miyaura cross-coupling reaction of (NH) free 3-bromo-indazol-5-amine with arylboronic acids under microwave-assisted conditions. The coupling reaction can be carried out under the conditions with dioxane/H2O as solvent, Pd(OAc)2 and RuPhos as catalyst system, and K3PO4 as a base in good to excellent yields.

Indazole compounds, compositions thereof and methods of treatment therewith

This invention is generally directed to the use of Indazole Compounds for treating or preventing diseases associated with protein kinases, including tyrosine kinases, such as proliferative diseases, inflammatory diseases, abnormal angiogenesis and diseases related thereto, atherosclerosis, macular degeneration, diabetes, obesity, pain and others. The methods comprise the administration to a patient in need thereof of an effective amount of an indazole compound that inhibits, modulates or regulates tyrosine kinase signal transduction. Novel indazole compounds or pharmaceutically acceptable salt thereof are presented herein.

Substituted indazoles, compositions containing them, method of production and use

Substituted indazoles, compositions containing them, method of production and use. The present invention relates in particular to novel specific substituted indazoles exhibiting kinase-inhibiting activity, having therapeutic activity, in particlar in onco

Methods for treating an inflammatory condition or inhibiting JNK

This invention is generally directed to Indazole Derivatives having the following structure: 1 or pharmaceutically acceptable salt thereof, wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of diseases and disorders that are responsive to JNK inhibition, such as an inflammatory disease or disorder. Thus, methods of treating such diseases and disorders are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

Indazole derivatives as JNK inhibitors and compositions and methods related thereto

Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.